Literature DB >> 26872915

From Bench to Bedside: Targeted Therapy, Denosumab, and 21st Century Orthopaedics: Targets Abound, But Where Are The Therapies?

Benjamin K Potter1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26872915      PMCID: PMC4773356          DOI: 10.1007/s11999-016-4734-2

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


× No keyword cloud information.
  14 in total

1.  Editorial: Getting Evidence Into Practice--or Not: The Case of Viscosupplementation.

Authors:  Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2015-11-16       Impact factor: 4.176

2.  Porcine small intestine submucosa augmentation of surgical repair of chronic two-tendon rotator cuff tears. A randomized, controlled trial.

Authors:  Joseph P Iannotti; Michael J Codsi; Young W Kwon; Kathleen Derwin; James Ciccone; John J Brems
Journal:  J Bone Joint Surg Am       Date:  2006-06       Impact factor: 5.284

3.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Authors:  David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

4.  Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report.

Authors:  Robin N Thompson; Ciara L Armstrong; Gary Heyburn
Journal:  Bone       Date:  2013-12-31       Impact factor: 4.398

5.  Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.

Authors:  Daniel G Branstetter; Scott D Nelson; J Carlos Manivel; Jean-Yves Blay; Sant Chawla; David M Thomas; Susie Jun; Ira Jacobs
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

6.  Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy.

Authors:  George R Matcuk; Dakshesh B Patel; Aaron J Schein; Eric A White; Lawrence R Menendez
Journal:  Skeletal Radiol       Date:  2015-02-26       Impact factor: 2.199

7.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

8.  A randomized trial of arthroscopic surgery for osteoarthritis of the knee.

Authors:  Alexandra Kirkley; Trevor B Birmingham; Robert B Litchfield; J Robert Giffin; Kevin R Willits; Cindy J Wong; Brian G Feagan; Allan Donner; Sharon H Griffin; Linda M D'Ascanio; Janet E Pope; Peter J Fowler
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

9.  Inhibition of 5-LOX, COX-1, and COX-2 increases tendon healing and reduces muscle fibrosis and lipid accumulation after rotator cuff repair.

Authors:  Nikhil R Oak; Jonathan P Gumucio; Michael D Flood; Anjali L Saripalli; Max E Davis; Julie A Harning; Evan B Lynch; Stuart M Roche; Asheesh Bedi; Christopher L Mendias
Journal:  Am J Sports Med       Date:  2014-09-22       Impact factor: 6.202

10.  Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.

Authors:  Piotr Rutkowski; Stefano Ferrari; Robert J Grimer; Paul D Stalley; Sander P D Dijkstra; Andrzej Pienkowski; Gualter Vaz; Jay S Wunder; Leanne L Seeger; Amy Feng; Zachary J Roberts; Bruce A Bach
Journal:  Ann Surg Oncol       Date:  2015-06-02       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.